Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

Propel: A Phase 1B, open-label, multicenter study to investigate the safety and preliminary efficacy of NKTR-214 in combination with Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in patients with locally advanced or metastatic solid tumors


General Information

Age Group




Protocol Number


Background Information

The purpose of this study is to test the safety, tolerability, and effectiveness of NKTR-214 given in combination with KEYTRUDA®

Offered At

Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital

Eligibility Information

  • Male/female participants with histologically confirmed locally advanced or metastatic melanoma (pembrolizumab only), locally advanced or metastatic urothelial carcinoma (atezolizumab only), or metastatic NSCLC (pembrolizumab only)
  • Additional eligibility in protocol

Ineligibility Information

  • Participants who have active or stable brain metastases or who have a history of brain metastases
  • Prior malignancy treated with anticancer therapy (including systemic chemotherapy, radiation and/or surgery) within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
  • Additional ineligibility in protocol

For more information go to: